Is AOD-9604 Legal in Maryland? How to Access It Legally

What AOD-9604 Is and Why Its Legal Status Is Complicated

AOD-9604 is a synthetic 16-amino-acid fragment of human growth hormone (hGH), specifically residues 176 to 191 of the hGH C-terminus. Researchers originally investigated it as an anti-obesity agent because animal data suggested it could stimulate lipolysis without the IGF-1-mediated growth effects of full hGH. It never received FDA approval for any indication.

The Peptide's Regulatory Identity Problem

The FDA does not classify AOD-9604 as a controlled substance under the Controlled Substances Act, which is administered by the DEA [1]. That distinction matters: the drug is not scheduled, so possession alone is not a criminal offense in the way that, say, anabolic steroids are. The problem is a different regulatory layer entirely, the Federal Food, Drug, and Cosmetic Act (FDCA), which prohibits introducing an unapproved new drug into interstate commerce without an approved New Drug Application (NDA) [2].

AOD-9604 has no approved NDA. The FDA reviewed it as part of its scrutiny of bulk drug substances used in compounding and, in guidance documents updated through 2023, declined to place it on the 503A bulks list of substances that compounding pharmacies may use without a finished FDA-approved drug to copy [3]. That single administrative decision is the core of its current legal complexity.

What Phase II Trials Actually Found

Metabolic Pharmaceuticals Ltd. Completed a Phase IIb trial (ClinicalTrials.gov NCT00131391) testing AOD-9604 at doses of 1 mg, 5 mg, and 10 mg per day orally in obese adults over 24 weeks. The trial found no statistically significant difference in weight loss between any AOD-9604 dose and placebo [4]. The company halted development of AOD-9604 as a weight-loss drug after those results. No Phase III data exists. This is why no NDA was ever filed and why FDA approval remains unavailable.

Federal Framework: FDA Compounding Rules That Govern Maryland Pharmacies

Maryland pharmacies do not operate in a legal vacuum. Federal compounding law, specifically Sections 503A and 503B of the FDCA, as amended by the Drug Quality and Security Act of 2013, sets the baseline that every state pharmacy board, including Maryland's, must work within [5].

503A: Patient-Specific Compounding

A 503A pharmacy is a traditional compounding pharmacy that prepares drugs for an identified individual patient based on a valid prescription from a licensed practitioner. To use a bulk drug substance (one that is not itself an FDA-approved finished drug) under 503A, the substance must appear on one of three lists:

1. The FDA's 503A bulks list (substances that may be used)
2. The FDA's negative list (substances that may not be used)
3. Substances under active FDA evaluation

AOD-9604 does not currently appear on the approved 503A bulks list [3]. The FDA's February 2024 guidance on peptides used in compounding specifically flagged several hGH-fragment peptides as raising safety and effectiveness concerns. A compounding pharmacy filling AOD-9604 prescriptions today is doing so in the absence of explicit FDA authorization, which exposes both the pharmacy and the prescribing physician to regulatory risk.

503B: Outsourcing Facilities

503B outsourcing facilities can produce drugs in larger batches without patient-specific prescriptions, but only using FDA-approved drugs as the starting point or bulk substances on a separate 503B-specific bulks list. AOD-9604 does not appear on that list either [6]. The 503B pathway for this peptide is effectively closed.

The FDA's Broader Peptide Crackdown

In March 2023, the FDA sent warning letters to multiple compounding pharmacies that were producing peptide products including AOD-9604, BPC-157, and TB-500, citing violations of the FDCA [7]. The FDA's position, stated explicitly in those letters, is that compounding facilities may not use bulk drug substances that have not been evaluated and placed on the appropriate compounding bulks list. Maryland-based pharmacies received no exemption from this federal enforcement posture.

Maryland State Law: What the State Adds (and Does Not Add)

Maryland does not have a statute that independently legalizes AOD-9604, nor does it have one that specifically bans it by name. The relevant Maryland legal framework operates through three bodies of law.

Maryland Health Code and Pharmacy Act

Maryland Health-General Article § 21-215 prohibits dispensing a prescription drug without a valid prescription from a licensed prescriber [8]. AOD-9604, when compounded and dispensed, functions as a prescription drug product under both federal and Maryland law. A pharmacist who dispenses it without a prescription violates state law. A patient who receives it without one is obtaining a prescription drug illegally.

The Maryland Board of Pharmacy enforces compliance with federal compounding standards under COMAR 10.34.13, which incorporates USP standards and requires pharmacies to operate consistently with federal law [9]. A Maryland pharmacy compounding AOD-9604 in the current regulatory environment takes on meaningful risk under both state board rules and federal FDA oversight.

Maryland Medical Practice Act

Maryland Health Occupations Article § 14-101 et seq. Governs physician licensure and the standard of care [10]. A Maryland physician who prescribes AOD-9604 off-label is not automatically violating the Medical Practice Act, off-label prescribing is legal and common across medicine. What the law requires is that the prescription reflect a legitimate clinical judgment made within the context of a valid physician-patient relationship. Prescribing a peptide with no FDA-approved indication and no Phase III efficacy data purely at a patient's request, without clinical documentation, raises standard-of-care questions that the Maryland Board of Physicians could investigate.

No Maryland Scheduling of AOD-9604

Maryland follows the federal controlled substances schedule (Md. Code, Crim. Law § 5-101 et seq.) with some state-specific additions [11]. AOD-9604 does not appear on any Maryland-specific schedule addition as of mid-2025. It is not a controlled substance in Maryland any more than it is at the federal level.

How Maryland Patients Currently Access AOD-9604 Legally

Given the regulatory framework above, legal access in Maryland is narrow but not zero. It requires all of the following conditions to be met simultaneously.

Step 1: A Valid Physician Prescription

A Maryland-licensed physician (MD or DO) must evaluate the patient, document a clinical rationale, and issue a prescription. Telehealth providers holding a Maryland license may do this, provided they establish a proper patient-provider relationship under Maryland telehealth standards [12]. The evaluation cannot be a rubber-stamp questionnaire. It needs a medical history, a documented clinical goal, and informed consent that includes disclosure of the limited efficacy evidence.

Step 2: A Pharmacy That Accepts the Risk

The compounding pharmacy filling the prescription must make its own legal determination that it can compound AOD-9604 under current FDA guidance. Some 503A pharmacies continue to compound certain peptides, accepting that they are doing so without explicit FDA bulks-list authorization and that enforcement risk exists. Others have stopped entirely after the 2023 warning letters [7]. Patients cannot control this variable, the pharmacy decides its own risk tolerance.

Step 3: No Interstate Sourcing Without a Prescription

Ordering AOD-9604 from an overseas or domestic online vendor labeled "for research use only" does not constitute legal access for human use. The FDA has stated that the "research use only" label does not exempt a substance from FDCA requirements when it is intended for human administration [2]. Maryland Health-General Article § 21-215 applies at the point of dispensing within the state [8].

The three-step framework above, prescription from a licensed Maryland provider plus a willing 503A pharmacy plus documented clinical rationale, represents the narrowest legally defensible path available to Maryland patients as of mid-2025. Any deviation from all three conditions moves the transaction into legally uncertain or clearly prohibited territory.

Clinical Evidence: What Patients and Prescribers Should Know

The evidence base for AOD-9604 in humans is thin. Prescribers operating within the standard of care need to communicate this honestly.

Weight Loss: Phase IIb Failure

The key human trial (NCT00131391) enrolled adults with a BMI of 27 to 35 kg/m² and tested oral AOD-9604 at 1 mg, 5 mg, and 10 mg daily for 24 weeks against placebo. No dose produced statistically significant weight loss compared to placebo [4]. The developer's own data halted the commercial program. There is no subsequent Phase III trial.

Animal and In Vitro Data

Rodent studies have shown that AOD-9604 can stimulate lipolysis in fat cells and reduce body fat in obese mice at doses of 250 to 500 mcg/kg [13]. These findings generated the original clinical interest. Animal lipolysis data do not translate directly to human clinical outcomes, and the Phase IIb trial confirmed this gap.

Safety Profile in Clinical Trials

The Phase IIb trial did not reveal major safety signals at the doses tested [4]. That absence of harm at clinical trial doses is meaningful but limited: it applies to short-term oral use in a monitored population. Long-term safety data for subcutaneous AOD-9604, the route used in most peptide clinics, does not exist in peer-reviewed literature.

Risks of Unregulated AOD-9604 Sources

Research-chemical vendors sell AOD-9604 online with no prescription requirement. Buying from these sources carries layered risks.

Purity is unverified. A 2021 analysis published in Drug Testing and Analysis examined peptide products sold online and found that 18 of 44 samples (41%) contained substances not listed on the label, including unlabeled active compounds [14]. For a peptide administered by subcutaneous injection, contamination with bacterial endotoxins or unlabeled pharmacological agents is a genuine harm vector.

Regulatory exposure is real. While the DEA does not schedule AOD-9604, the FDA can take action against individuals who import unapproved drugs. The FDA's personal importation policy allows discretion for small quantities of drugs for personal use, but that discretion does not apply to substances the FDA considers to pose safety concerns [15].

The American Association of Clinical Endocrinology (AACE) guidelines on obesity pharmacotherapy, updated in 2023, do not include AOD-9604 or other unapproved peptides in the recommended treatment algorithm [16]. A patient using an unregulated peptide instead of a guideline-recommended agent (semaglutide, tirzepatide, phentermine/topiramate) is forgoing treatments with Phase III efficacy data and FDA approval.

Alternatives With Established FDA Status and Maryland Availability

For patients seeking weight management support in Maryland, several FDA-approved options carry genuine Phase III evidence.

Semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo in STEP-1 (N = 1,961) [17]. Tirzepatide 15 mg (Zepbound) produced up to 22.5% mean weight reduction at 72 weeks in SURMOUNT-1 (N = 2,539) [18]. Both are FDA-approved, covered by growing numbers of Maryland insurance plans, and available through telehealth prescribers holding Maryland licenses.

These agents are not relevant to every patient. But a Maryland physician discussing AOD-9604 with a weight-loss-motivated patient has an ethical obligation to present the evidence contrast: Phase IIb failure for AOD-9604 versus Phase III success with semaglutide and tirzepatide.

What Maryland Telehealth Providers Can and Cannot Do

Maryland enacted the Interstate Medical Licensure Compact (IMLC), making it easier for out-of-state physicians to hold Maryland licenses [12]. Telehealth companies operating across the country can legally prescribe to Maryland patients if a Maryland-licensed provider conducts the evaluation.

What telehealth providers cannot legally do in Maryland: prescribe AOD-9604 without a proper clinical evaluation, use a questionnaire as a substitute for a patient-provider relationship, or direct patients to pharmacies that ship controlled or unapproved drug products without valid prescriptions. Maryland's telehealth standard-of-care requirements parallel its in-person requirements under the Medical Practice Act [10].

The Maryland Board of Pharmacy and the Board of Physicians both have authority to investigate complaints arising from telehealth peptide prescribing. That authority extends to the prescriber's license regardless of where the telehealth company is incorporated.